Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes

members of the Kidney Cancer group of the CCAFU

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.

Original languageEnglish
Pages (from-to)35.e15-35.e19
JournalUrologic Oncology: Seminars and Original Investigations
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Nephrons
Carcinoma
Renal Cell Carcinoma
Neoplasms
Recurrence
Survival
Kidney Neoplasms
Multicenter Studies
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. / members of the Kidney Cancer group of the CCAFU.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 35, No. 1, 01.01.2017, p. 35.e15-35.e19.

Research output: Contribution to journalArticle

@article{564922f48bc84aea9df9609ea2ad0d34,
title = "Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes",
abstract = "Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6{\%}) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6{\%}). Pathologic stages were T1, T2, and T3a in 202 (86.3{\%}), 9 (3.8{\%}), and 23 (9.8{\%}) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8{\%}) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1{\%} and 100{\%}, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.",
author = "{members of the Kidney Cancer group of the CCAFU} and Pierre Bigot and Bernhard, {Jean Christophe} and Vincent Flamand and Inderbir Gill and Gr{\'e}gory Verhoest and Beauval, {Jean Baptiste} and Nouhaud, {Fran{\cc}ois Xavier} and Evren Suer and Guillaume Ploussard and Hetet, {Jean Fran{\cc}ois} and J{\'e}r{\^o}me Rigaud and Eduard Baco and St{\'e}phane Larr{\'e} and Philippe Sebe and Nicolas Koutlidis and Aur{\'e}lien Descazeaud and Masatoshi Eto and Arnaud Doerfler and Morgan Roupret and Vuong, {Nam Son} and Boris Reix and Toru Matsugasumi and Bakri, {Adnan El} and Laurence Albiges and Michel Souli{\'e} and Patard, {Jean Jacques} and Arnaud M{\'e}jean and Karim Bensalah",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2016.08.012",
language = "English",
volume = "35",
pages = "35.e15--35.e19",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes

AU - members of the Kidney Cancer group of the CCAFU

AU - Bigot, Pierre

AU - Bernhard, Jean Christophe

AU - Flamand, Vincent

AU - Gill, Inderbir

AU - Verhoest, Grégory

AU - Beauval, Jean Baptiste

AU - Nouhaud, François Xavier

AU - Suer, Evren

AU - Ploussard, Guillaume

AU - Hetet, Jean François

AU - Rigaud, Jérôme

AU - Baco, Eduard

AU - Larré, Stéphane

AU - Sebe, Philippe

AU - Koutlidis, Nicolas

AU - Descazeaud, Aurélien

AU - Eto, Masatoshi

AU - Doerfler, Arnaud

AU - Roupret, Morgan

AU - Vuong, Nam Son

AU - Reix, Boris

AU - Matsugasumi, Toru

AU - Bakri, Adnan El

AU - Albiges, Laurence

AU - Soulié, Michel

AU - Patard, Jean Jacques

AU - Méjean, Arnaud

AU - Bensalah, Karim

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.

AB - Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.

UR - http://www.scopus.com/inward/record.url?scp=85002822797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002822797&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.08.012

DO - 10.1016/j.urolonc.2016.08.012

M3 - Article

C2 - 27692834

AN - SCOPUS:85002822797

VL - 35

SP - 35.e15-35.e19

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -